Investigating Hereditary Risk In Thoracic Cancers (INHERIT) — INHERIT  

Lung Cancer Clinical Trial

Official title: Investigating Hereditary Risk In Thoracic Cancers (INHERIT)

Status Recruiting

Clinical Trial Summary

The purpose of this research study is to learn more about the inherited risk for developing lung cancer.

Clinical Trial Description

Lung cancer is largely tobacco related, but the contribution of inherited susceptibility has been less well-studied, particularly among never-smokers. The goal of this study is to learn more about genetic susceptibility to lung cancer by studying individuals and families with known pathogenic germline mutations and/or family histories suggestive for heritable lung cancer, specifically in cases where tobacco exposure is minimal. Patients will be identified through somatic multi-gene panel testing (MGPT) as well as through reported personal and family histories of one or multiple cancers.

The overriding goal of this protocol is to follow patients with known germline mutations and strong family histories of lung cancer to better determine their risk of lung cancer and inform a screening paradigm based on this risk. This will allow us to observe the natural history of this disease and better understand the mechanisms underlying lung tumorigenesis in patients with susceptible germline backgrounds. These patients and their families will be enrolled as individuals with or without lung cancer who meet the following criteria: 1) individuals known to carry or at risk for carrying a germline EGFR mutation (T790M or other), identified through family members or by somatic genotyping at diagnosis, 2) individuals known to carry or at risk for carrying a pathogenic germline mutation in genes other than EGFR and with family history of lung cancer, or 3) individuals with no known germline mutation but with minimal exposure to tobacco and family history of lung cancer, personal history of other primary cancers, or multi-focal lung cancer.

This study is designed to create a data and specimen repository as well as follow patients over time to learn how to better predict lung cancer risk for those with certain genetic changes and family history of lung cancer, and to better understand how and why lung cancer develops in families.

The research study procedures include screening for eligibility, collection of information from participants' medical record, short questionnaires, and collecting blood and/or saliva samples. Procedures may also include use of tissue samples, access to medical records and stored specimens from deceased relatives, and contact information of family members.

It is expected that about 500 people will participant in this study. ;

Related Conditions & MeSH terms

• Disease Susceptibility
• Genetic Disease
• Genetic Diseases, Inborn
• Genetic Predisposition
• Genetic Predisposition to Disease
• Hereditary Diseases
• Lung Cancer

• NCT number: NCT05587439
• Study type: Observational
• Source: Dana-Farber Cancer Institute
• Contact: Pasi A Jänne, MD, PhD
• Phone: 617-632-6036
• Email: Pasi_Janne@dfci.harvard.edu
• Status: Recruiting
• Start date: January 1, 2023
• Completion date: November 1, 2027